Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
{iframe}https://www.businesswire.com/news/home/20180425005032/en/Corvidia-Therapeutics-Secures-60-Million-Series-Funding{/iframe}